ORMP - Oramed granted U.S. combination therapy patent for oral insulin

Oramed Pharma (NASDAQ:ORMP) said on Tuesday that the United States Patent and Trademark Office had granted a patent for methods and compositions for treating diabetes. The patent is for methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1. Oramed is a platform technology in the field of oral delivery solutions for drugs currently delivered via injection. In December, Oramed's subsidiary inks purchase deal for 10M doses of oral COVID-19 vaccines in Southeast Asia.

For further details see:

Oramed granted U.S. combination therapy patent for oral insulin